Elevance Health (NYSE:ELV) Stock Acquired Rep. Lisa C. McClain

Key Points

• Representative Lisa C. McClain purchased shares of Elevance Health, Inc. (NYSE:ELV) valued between $1,001 and $15,000 on July 10th.
• Elevance Health recently announced a quarterly dividend of $1.71 per share, with a yield of 2.2%, to be paid on September 25th.
• Analysts have set a consensus price target of $413.81 for Elevance Health, with ratings ranging from "buy" to "hold" from various research firms.

Representative Lisa C. McClain (R-Michigan) recently bought shares of Elevance Health, Inc. NYSE: ELV. In a filing disclosed on August 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in Elevance Health stock on June 24th. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Autoliv NYSE: ALV on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Arthur J. Gallagher & Co. NYSE: AJG on 8/4/2025.
• Sold $1,001 - $15,000 in shares of SAP NYSE: SAP on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of XPO NYSE: XPO on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Lithia Motors NYSE: LAD on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Sanofi NASDAQ: SNY on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Waters NYSE: WAT on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Group 1 Automotive NYSE: GPI on 7/22/2025.

Elevance Health Stock Down 0.4%

Shares of Elevance Health stock traded down $1.3310 during trading on Wednesday, reaching $310.6690. The company's stock had a trading volume of 2,134,644 shares, compared to its average volume of 2,721,708. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $567.26. The company has a 50-day simple moving average of $327.09 and a two-hundred day simple moving average of $379.97. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64. The company has a market cap of $69.96 billion, a price-to-earnings ratio of 13.22, a P/E/G ratio of 1.14 and a beta of 0.58.

Elevance Health (NYSE:ELV - Get Free Report) last released its quarterly earnings results on Thursday, July 17th. The company reported $8.84 EPS for the quarter, missing analysts' consensus estimates of $9.30 by ($0.46). The business had revenue of $49.42 billion during the quarter, compared to analysts' expectations of $48.26 billion. Elevance Health had a net margin of 2.83% and a return on equity of 17.59%. The company's quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter last year, the business posted $10.12 earnings per share. As a group, equities analysts forecast that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 25th. Stockholders of record on Wednesday, September 10th will be given a $1.71 dividend. The ex-dividend date of this dividend is Wednesday, September 10th. This represents a $6.84 dividend on an annualized basis and a dividend yield of 2.2%. Elevance Health's dividend payout ratio (DPR) is presently 29.11%.

Analyst Ratings Changes

A number of analysts recently commented on ELV shares. Robert W. Baird lowered their target price on shares of Elevance Health from $492.00 to $297.00 and set a "neutral" rating for the company in a research note on Friday, July 25th. Morgan Stanley lowered their price objective on shares of Elevance Health from $428.00 to $316.00 and set an "overweight" rating for the company in a research note on Friday, July 18th. Argus reissued a "hold" rating on shares of Elevance Health in a research report on Monday, July 21st. UBS Group restated a "buy" rating and issued a $484.00 target price (down previously from $555.00) on shares of Elevance Health in a research note on Monday, July 14th. Finally, JPMorgan Chase & Co. dropped their price target on Elevance Health from $472.00 to $384.00 and set an "overweight" rating on the stock in a research note on Tuesday, July 22nd. Twelve research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, Elevance Health has a consensus rating of "Moderate Buy" and an average price target of $413.81.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. CWA Asset Management Group LLC purchased a new position in shares of Elevance Health during the 1st quarter valued at approximately $299,000. GAMMA Investing LLC increased its holdings in Elevance Health by 88.1% in the first quarter. GAMMA Investing LLC now owns 3,390 shares of the company's stock valued at $1,475,000 after buying an additional 1,588 shares in the last quarter. Ritholtz Wealth Management raised its position in shares of Elevance Health by 185.7% in the first quarter. Ritholtz Wealth Management now owns 3,083 shares of the company's stock worth $1,341,000 after acquiring an additional 2,004 shares during the period. Sequoia Financial Advisors LLC boosted its stake in shares of Elevance Health by 15.7% during the 1st quarter. Sequoia Financial Advisors LLC now owns 6,717 shares of the company's stock worth $2,922,000 after acquiring an additional 913 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its position in shares of Elevance Health by 36.8% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 27,566 shares of the company's stock valued at $11,991,000 after acquiring an additional 7,410 shares during the period. 89.24% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Elevance Health news, CEO Gail Boudreaux purchased 8,500 shares of Elevance Health stock in a transaction that occurred on Friday, July 18th. The stock was bought at an average price of $286.94 per share, with a total value of $2,438,990.00. Following the acquisition, the chief executive officer owned 151,020 shares of the company's stock, valued at $43,333,678.80. This trade represents a 5.96% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.29% of the company's stock.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.